Endocrinology Archives

GlucoMetrics says it can beat glucose monitoring competition on accuracy

November 12, 2010 By MedCity News Leave a Comment

Diabetics have a problem, and an Ohio startup thinks its technology has what it takes to solve it.

Blood glucose monitoring technology isn’t as accurate as it could be, and that lack of accuracy poses a health risk to diabetics, particularly those suffering from hypoglycemia said Bill Timmons, CEO of Columbus-based GlucoMetrics Inc. The condition can bring fainting or seizures, in serious cases, and occurs when a patient’s blood glucose is too low. It can be brought on by excessive amounts of insulin.

GI Dynamics inks UK distribution deal

September 1, 2010 By MassDevice staff Leave a Comment

GI Dynamics inked a deal for distribution of its EndoBarrier anti-obesity and Type II diabetes device in the United Kingdom.

The Lexington, Mass.-based firm said Hungerford, England-based Elemental Healthcare will distribute the device, a gut liner designed to inhibit the absorption of food to induce weight loss and help control the symptoms of diabetes, in England, Wales, Scotland, Northern Ireland and Ireland.

Insulet COO Malave jumps ship to helm Palyon Medical

August 17, 2010 By MassDevice staff Leave a Comment

Luis Malave, COO for Insulet Corp. (NSDQ:PODD), is jumping ship effective August 31 to man the helm of Palyon Medical Corp.

Malave’s eight-year tenure at the Bedford, Mass.-based insulin management system maker saw the company ramp up its capabilities to produce 1 million of Insulet’s flagship OmniPods per quarter.

Medtronic touts insulin pump trial data

June 29, 2010 By MedCity News Leave a Comment

By Brandon Glenn

Medtronic Inc. (NYSE:MDT) reported that a clinical trial showed its insulin pump system with a sensor helped patients with Type I diabetes control their glucose levels better than multiple daily injections.

Insulet’s Q1 earnings beat Wall Street’s forecast by a penny

May 7, 2010 By MassDevice staff Leave a Comment

Riding a 67 percent jump in first quarter revenues, insulin pump-maker Insulet Corp. (NSDQ:PODD) significantly narrowed its net loss compared to year-ago levels and beat Wall Street estimates by 1 cent per share during the three months ended March 31.

CeQur taps J&J vet as new regulatory chief

April 13, 2010 By MassDevice staff Leave a Comment

CeQur SA named a Johnson & Johnson (NYSE:JNJ) veteran to be its new executive vice president of regulatory affairs.

Robert O’Holla will oversee regulatory strategy for the Swiss firm, which has its U.S. headquarters in Marlborough, Mass. CeQur is developing an insulin delivery system for patients with Type II diabetes.

Medtronic aims to establish its Revel in the race for an artificial pancreas

March 31, 2010 By MedCity News Leave a Comment

By Thomas Lee

Medtronic Inc. (NYSE:MDT) first gained fame by developing devices that could automatically zap an errant heart back into rhythm. Now the medical device giant wants to apply the same approach to the wayward pancreas.

UPDATE: Medtronic wins FDA nod for diabetes system, files for cryoablation PMA

March 17, 2010 By MassDevice staff Leave a Comment

Medtronic Inc. (NYSE:MDT) won a supplemental PMA from the Food & Drug Administration for the latest version of its MiniMed Paradigm REAL-Time diabetes management system, which it touts as the “industry’s only integrated diabetes management system.”

And the Fridley, Minn.-based medical devices monolith put another product into the PMA pipeline, its Arctic Front cryoablation catheter system, after revealing positive study results at a recent conference.

Echo Therapeutics nears clinical trial for Symphony glucose monitor

February 19, 2010 By MassDevice staff Leave a Comment

Echo Therapeutics Inc. (OTC:ECTE) said it’s made a "significant advance" in the design of its Symphony transdermal glucose monitor that could see it soon begin a clinical trial of the device.

The Franklin, Mass.-based company said the breakthrough will make the electronic component of the device one-third smaller compared with its prototype and plans to complete product development for the entire system "in the near-term," meaning clinical trials could be just around the corner.

Insulet beats Q4, full-year expectations

February 9, 2010 By MassDevice staff Leave a Comment

Insulet Corp. (NSDQ:PODD) continued down the road to profitability, increasing its fourth-quarter and full-year revenues and narrowing its net losses by 48.9 percent and 16.1 percent, respectively.

The Bedford, Mass.-based insulin management system maker posted a net loss of $14.9 million, or 42 cents per share, on sales of $20.2 million during the three months ended Dec. 31, 2009, compared with net losses of $29.2 million, or $1.05 per share, on sales of $11.9 million during the fourth quarter of 2008.

MassDevice Q&A: CeQur CEO Jim Peterson

January 21, 2010 By Brad Perriello Leave a Comment

Jim Peterson spent the better part of 20 years helping to improve the quality of the world’s blood supply at Haemonetics Corp. (NYSE:HAE), where he was CEO from 1998 to 2003. And while he was passionate about the importance of that work, his new role as chief executive for CeQur Ltd. might be even closer to his heart.

Peterson spoke with MassDevice just before giving a presentation on the patch-like device CeQur is developing for insulin delivery at the OneMedPlace Finance Forum in San Francisco Jan. 13. He told us about the personal connection he feels to his current work, which stems from the fact that his daughter has diabetes, and why he sees Montreux, Switzerland-based CeQur’s device as a potential market leader.